Last Updated: June 24, 2026

NINTEDANIB Drug Patent Profile

Name: NINTEDANIB Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Nintedanib, and what generic alternatives are available?

Nintedanib is a drug marketed by Apotex, Cipla, Dexcel, Dr Reddys, and Sandoz. and is included in five NDAs.

The generic ingredient in NINTEDANIB is nintedanib esylate. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the nintedanib esylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nintedanib

A generic version of NINTEDANIB was approved as nintedanib esylate by APOTEX on April 2^nd, 2026.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for NINTEDANIB?
What are the global sales for NINTEDANIB?
What is Average Wholesale Price for NINTEDANIB?

Summary for NINTEDANIB

US Patents:	0
Applicants:	5
NDAs:	5
DailyMed Link:	NINTEDANIB at DailyMed

Drug patent expirations by year for NINTEDANIB

US Patents and Regulatory Information for NINTEDANIB

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	NINTEDANIB ESYLATE	nintedanib esylate	CAPSULE;ORAL	219227-001	Apr 2, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dr Reddys	NINTEDANIB ESYLATE	nintedanib esylate	CAPSULE;ORAL	219283-001	Apr 2, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Cipla	NINTEDANIB ESYLATE	nintedanib esylate	CAPSULE;ORAL	212609-002	Apr 2, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for NINTEDANIB

Nintedanib patent expiration?
Nintedanib patent expiry date?
Nintedanib 100 mg generic medicine?
Nintedanib patent expiry 2029?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.